In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
about
Clostridium difficile infection: molecular pathogenesis and novel therapeuticsVariations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficileMolecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in ThailandThe challenges posed by reemerging Clostridium difficile infection.Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolateClostridium difficile infection in an endemic setting in the NetherlandsClostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB.Clostridium difficile: improving the prevention paradigm in healthcare settings.Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated diseaseSeasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.Antimicrobial-resistant strains of Clostridium difficile from North America.Detection of Clostridium difficile in retail ground meat products in ManitobaIncreased sporulation rate of epidemic Clostridium difficile Type 027/NAP1Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaksRifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct.Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.Clinical update for the diagnosis and treatment of Clostridium difficile infection.Clostridium difficile colonization in preoperative colorectal cancer patients.Current state of Clostridium difficile treatment options.Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern ChinaMultidrug resistance in European Clostridium difficile clinical isolates.Clostridium difficile RT 078/ST11: A Threat to Community Population and Pigs Identified in Elder Hospitalized Patients in Beijing, China.TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing.In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficileClindamycin-resistant clone of Clostridium difficile PCR Ribotype 027, Europe.Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens.Detection of cross-infection associated to a Brazilian PCR-ribotype of Clostridium difficile in a university hospital in Rio de Janeiro, Brazil.Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.
P2860
Q26864237-E6160037-623D-468D-834B-9C309E623278Q28475218-D4DA3CD8-B006-47C1-977E-C6CFF382CF98Q28547441-E51693C6-2A7E-4940-A594-86B8D9E83552Q30229530-634036ED-5782-4123-8B1A-BE6BA3977706Q33782277-BDBFE4C5-57E1-43C3-9534-26F072A2652CQ34562315-9D55044A-2937-4394-BF13-7D4979E6BCE6Q34641408-2970D42B-D567-44A0-BF60-A58C6DED646FQ34916871-0C650236-91D3-4701-8DBD-CF4C40658147Q35222472-1D99CB53-34F7-470B-83F8-93103C963B24Q35621057-7F8AB53A-D5FC-4387-8850-17203DC9A648Q35689261-EE18CD0E-AAE4-4278-A5AB-1568CA2E2BADQ36018766-E526A96C-7E23-4446-8227-FEDE750E47E9Q36029505-D898FD57-7CFC-4E4F-B416-E39E6BF65BE3Q36539739-EBE7D4E8-BB1A-4EC5-B011-A0DE551C6871Q36970016-FB30FC0F-D09A-41DB-9C3E-6FE2506272A1Q37145568-3FF95F5E-04C4-4766-9278-753E65B34E97Q37166525-E151911D-3B0A-498E-81E5-C9C86AE5C2A9Q37569179-4B327B8D-CB7D-4B46-A5D1-381DC7FE8D77Q37633859-90F27C75-836E-4867-A8D7-4F82A1618F04Q37707006-AAD287FC-49BB-48A1-BDD0-E9814D41A9F1Q38023283-1E66288A-AC4E-4741-A205-261D88F7B0D3Q39038610-B5E20A31-EF40-4585-BE65-19CD26DD2F62Q39727030-A7F2CA13-D320-4E80-997C-2712853BA3FEQ41993942-C0CC7F72-3B30-455B-A87D-316594B2C415Q42009793-911DDCE9-FB28-4047-AEB5-AD380D825F2BQ42261294-A7D58B42-F9E5-4D41-AE5D-4BF5A7CD2966Q43227675-5671A553-75FE-4098-9391-DFEFD257744BQ46277734-B4130F08-4CF2-40D6-9553-FF3165677344Q51761286-E42321E6-49A7-43AD-AEF7-2ECD44651891Q53692769-1E8BD91E-E420-4F76-ACCD-0528A345D38A
P2860
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
In vitro susceptibility of Clo ...... ak in Southern Québec, Canada.
@en
type
label
In vitro susceptibility of Clo ...... ak in Southern Québec, Canada.
@en
prefLabel
In vitro susceptibility of Clo ...... ak in Southern Québec, Canada.
@en
P2093
P2860
P356
P1476
In vitro susceptibility of Clo ...... ak in Southern Québec, Canada.
@en
P2093
Anne-Marie Bourgault
CDAD-CSI Study Group
François Lamothe
Louise Poirier
Vivian G Loo
P2860
P304
P356
10.1128/AAC.00479-06
P407
P577
2006-10-01T00:00:00Z